Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification
暂无分享,去创建一个
K. Strebhardt | M. Sanhaji | S. Becker | M. Tahmasbi Rad | M. Raab | E. Kurunci-Csacsko | Khayal Gasimli